A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?

2009 ◽  
Vol 64 (5) ◽  
pp. 929-937 ◽  
Author(s):  
A. M. M. Y. Li ◽  
C. D. Gomersall ◽  
G. Choi ◽  
Q. Tian ◽  
G. M. Joynt ◽  
...  
Keyword(s):  
Systematic Review ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Sufficient Data ◽  
Dosing Regimens ◽  
Antibiotic Dosing

scholarly journals Imipenem dosing recommendations for patients undergoing continuous renal replacement therapy: systematic review and Monte Carlo simulations

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Dhakrit Rungkitwattanakul ◽  
Taniya Charoensareerat ◽  
Pathakorn Kerdnimith ◽  
Nutsinee Kosumwisaisakul ◽  
Piyakamol Teeranaew ◽  
...  
Keyword(s):  
Systematic Review ◽  
Monte Carlo ◽  
Renal Replacement Therapy ◽  
Monte Carlo Simulations ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Optimal Dose ◽  
Pharmacokinetic Parameters ◽  
Pharmacokinetic Studies ◽  
Dosing Regimens

Abstract Background The appropriate dosing of imipenem for critically ill AKI patients undergoing CRRT remains scarce. Purpose This study aimed to (1) gather the available published pharmacokinetic studies conducted in septic patients receiving continuous renal replacement therapy (CRRT) and (2) to define the optimal imipenem dosing regimens in these populations via Monte Carlo simulations. Methods The databases of PubMed, Embase, and ScienceDirect were searched from inception to May 2020. We used the Medical Subject Headings of “Imipenem,” “CRRT,” and “pharmacokinetics” or related terms or synonym to identify the studies for systematic reviews. A one-compartment pharmacokinetic model was conducted to predict imipenem levels for the initial 48 h of therapy. The pharmacodynamic target was 40% of free drug level above 4 times of the MIC (40% fT > 4 MIC). The dose that achieved at least 90% of the probability of target attainment was defined as an optimal dose. Results Eleven articles were identified and included for our systematic review. The necessary pharmacokinetic parameters such as the volume of distribution and the CRRT clearance were mentioned in 100 and 90.9%, respectively. None of the current studies reported the complete necessary parameters. A regimen of 750 mg q 6 h was the optimal dose for the predilution-CVVH and CVVHD modality with two effluent rates (25 and 35 mL/kg/h) for the pharmacodynamic target of 40% fT > 4MIC. Conclusions None of the current studies showed the complete necessary pharmacokinetic parameters for drug dosing. Pharmacodynamic target significantly contributed to imipenem dosing regimens in these patients. Different effluent rates and types of CRRT had minimal impact on dosing regimens. Clinical validation of the recommendation is necessary.

Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy

2017 ◽  
Vol 44 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Weerachai Chaijamorn ◽  
Alexander R. Shaw ◽  
Susan J. Lewis ◽  
Bruce A. Mueller
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Important Determinant ◽  
Ex Vivo ◽  
Pharmacokinetic Parameters ◽  
No Adsorption ◽  
Continuous Hemofiltration ◽  
Flow Rates ◽  
Dosing Regimens

Background/Aims: To determine ceftolozane/tazobactam transmembrane clearances (CLTM) in continuous hemofiltration (CHF) and continuous hemodialysis (CHD) and to determine optimal ceftolozane/tazobactam dosing regimens for patients receiving continuous renal replacement therapy (CRRT). Method: Validated, ex vivo CHF and CHD bovine blood models using polysulfone (HF1400) and AN69 (Multiflow 150-M) hemofilters were used to evaluate adsorption and CLTM at different effluent flow rates. Monte Carlo simulations (MCS) using pharmacokinetic parameters from published studies and CLTM from this study were used to generate ceftolozane/tazobactam dosing for patients receiving CRRT. Results: CHF and CHD CLTM did not differ at equivalent effluent rates. CLTM approximated effluent flow rates. No adsorption of ceftolozane/tazobactam occurred for either hemofilter. Effluent flow was the most important determinant of MCS-derived doses. Conclusion: CRRT clearances of ceftolozane/tazobactam depended on effluent flow rates but not hemofilter types. MCS-derived ceftolozane/tazobactam doses of 750 (500/250)-1,500 (1,000/500) mg every 8 h met pharmacodynamic targets for virtual patients receiving CRRT at contemporary effluent rates.

Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review

2016 ◽  
Vol 43 (6) ◽  
pp. 750-763 ◽  
Author(s):  
Oleksa G. Rewa ◽  
Pierre-Marc Villeneuve ◽  
Philippe Lachance ◽  
Dean T. Eurich ◽  
Henry T. Stelfox ◽  
...  
Keyword(s):  
Systematic Review ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Critically Ill ◽  
Quality Indicators ◽  
Critically Ill Patients

The dose of continuous renal replacement therapy for acute renal failure: a systematic review and meta-analysis

Renal Failure ◽  
2010 ◽  
Vol 32 (5) ◽  
pp. 555-561 ◽  
Author(s):  
Edward T. Casey ◽  
Bhanu P. Gupta ◽  
Patricia J. Erwin ◽  
Victor M. Montori ◽  
M. Hassan Murad
Keyword(s):  
Systematic Review ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document